Table 4.
Summary of changes in recommended antithrombotic strategy due to change in AHA Z-score classification with conversion from Boston to PHN models
| Change in antithrombotic strategya (Boston → PHN) | Acute* (N = 175) | Subacute (N = 112) | Convalescent (N = 93) | All phases (N = 380) |
|---|---|---|---|---|
| No change | 173 (98.9%) | 106 (94.6%) | 22 (23.7%) | 301 (79.2%) |
| Increase intensity | ||||
| No anticoagulation → anticoagulation recommended | – | 2 (1.8%) | 1 (1.1%) | 3 (0.8%) |
| Stop ASA → continue ASA | – | – | 55 (59.1%) | 55 (14.5%) |
| Decrease intensity | ||||
| Anticoagulation → no anticoagulation | 2 (1.1%) | 4 (3.6%) | 1 (1.1%) | 7 (1.8%) |
| Continue ASA → stop ASA | – | – | 14 (15.0%) | 14 (3.7%) |
aAntithrombotic Strategies- Coronary artery z-scores ≥ 10 treated with anticoagulant (warfarin or low molecular weight heparin) and ASA. In the convalescent phase, z-scores ≥ 2.0 would continue ASA, whereas ASA can be stopped if < 2.0 [1]
*N refers to total number of z-scores reclassified with conversion from Boston to PHN models at each phase